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Asthma in the elderly is poorly understood because only a small minority of asthma studies have
investigated this patients group. Fractional Exhaled Nitric Oxide (FENO) has been extensively
studied in children and adults with asthma, but little is known about FENO in elderly asthmatics.
We studied the role of serial measurements of FENO in elderly subjects with asthma.
Thirty stable asthmatics 65 years old and older were followed for one year with evaluations at
baseline and every threemonths.We looked for associations between FENO and subjects’ demo-
graphics, comorbidities, asthma treatment, spirometric values and Asthma Control Test (ACT)
scores. FENO was not elevated in our study subjects throughout the study period
(mean< 30 ppb). FENO significantly increased and FEV1% decreased between first and last study
visit, while ACT scores and steroid dose remained unchanged. No significant correlation was
found between FENO and FEV1/FVC, other spirometric values, inhaled steroid dose or ACTscores
at any time point. No associations of FENO were found with age, sex, Body Mass Index (BMI),
atopic status, disease duration, presence of rhinitis or gastroesophageal reflux disease (GERD),
or other medications used. Moderate asthma exacerbations did not consistently cause an in-
crease of FENO.
In stable elderly asthmatic patients, FENO was not elevated and did not correlate with sub-
jects’ demographics, comorbidities, treatment, symptoms or spirometric values. Routine mea-
surements of FENO may not be clinically valuable in elderly asthmatics.
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Table 1 Subjects’ characteristics at baseline.
Female/male 18/12
Age, yr (range) 71.6  4.9 (65e84)
BMI (range) 25.6  3.8 (19e34)
Atopy 21/30
Duration of disease,
yr (range)
35  20.3 (2e70)
Inhaled steroids (dose) 26/30 (384  378 mcg/day)
Long acting bronchodilator 20/30
Leukotriene antagonist 11/30
Theophylline 2/30
Prednisone 2/30
Inhaled anticholinergic 1/30
Nasal steroids 15/30
Rhinitis 27/30
Nasal polyps 2/30
GERD 12/30
Heart disease 3/30
ACT score 22.1  2.8
FENO (ppb) 18.2  14.3
FEV1 (%) 84.9  20.3
FEV1/FVC 0.71  0.08
FEF25e75% 64.2  29.5
Results are expressed as the mean  S.D. Of the two subjects on
prednisone at baseline, in one it was discontinued shortly after
the initial visit, in the other it was reduced from 10 mg/day to
2.5 mg/day for the rest of the study period.U.S. population by the year 2050. Most studies on asthma
have not included elderly asthmatics who are more likely to
be underdiagnosed, undertreated, and hospitalized when
compared to their younger counterparts.1 Pulmonary
function tests and monitoring asthmatic symptoms may be
less reliable in the elderly because of other potential cau-
ses of respiratory impairment and delayed awareness of
bronchoconstriction. Elderly asthmatics have an increased
mortality compared to their non-asthmatic counterparts.1
FENO has been proposed as a marker of airway eosino-
philic inflammation, but the role of FENO measurements in
patients with asthma remains unclear. To our knowledge,
no study has addressed the value of serial FENO measure-
ments in older asthmatics. Therefore, we performed such
measurements every three months for one year in a group
of elderly, stable asthmatic patients. We looked for asso-
ciations between FENO and subjects’ demographics,
comorbidities, asthma treatment, spirometric values and
ACT scores.
Thirty subjects 65 years old and older with asthma fol-
lowed in an Allergy and Immunology practice in suburban
Philadelphia were included in the study. Twenty-five study
subjects were lifetime nonsmokers and five smoked for less
than 10 pack-years. The study was approved by the Main
Line Hospitals Institutional Review Board.
The presence of atopy was verified by allergy skin tests.
Spirometric values were obtained by KoKo Spirometer
(nSpire Health, Inc, Longmont, CO). FENO was measured
online in triplicate determinations by NIOX MINO (Aero-
crine, New Providence, NJ) according to the ATS/ERS
guidelines and reported in ppb as the mean of the three
values.
Statistical analysis was performed using STATA v10
(College Station, TX). Descriptive variables were expressed
as means and standard deviation, Multiple linear regression
was used to test association between groups of variables
and group differences were tested using unpaired t-tests.
Significance was accepted at alpha Z 0.05 with no
adjustment for multiple comparisons.
Table 1 shows the study subjects’ characteristics at
baseline. We found that FENO was not elevated
(mean < 30 ppb at each of the four study visits) and there
were no significant differences between any of the values
of FENO, FEV1% and ACT scores at each study visit and the
ones obtained at the previous visit. However, there was a
significant increase in FENO (to 27  14.5 ppb, p Z 0.02)
and a decrease of the FEV1% (to 71.3  15.8%, p Z 0.005)
between the first and the last visits, while ACT scores
(22.1  2.8 vs. 22.3  3.3) and inhaled steroid dose
(353  363 vs. 375  374 mcg/day) were unchanged.
We found no association between FENO and age, sex,
BMI, atopic status, disease duration, rhinitis, or GERD
(p > 0.34 for all measurements).
We found no association between FENO and inhaled
steroid dose, treatment with a long-acting bronchodilator,
leukotriene antagonist, or nasal steroid (p > 0.18 for all
measurements). FENO was higher in the subjects who were
not receiving inhaled steroids (36.8  16.1 vs.
24.2  19.2 ppb, visit 3, n Z 6 and 24, respectively),
whereas ACT (20.8 vs. 21.3) and FEV1% (71.9% vs. 73.5%)were unchanged. This difference did not reach statistical
significance (pZ 0.11), possibly due to the small number of
untreated subjects.
We found no association between FENO and ACT scores
or spirometric values, except for FEV1% and FEF25e75% at
visit 2 (p < 0.04). When ACT scores were 19 (17.2  1.5,
n Z 5), FENO was low (11.6  3.9 ppb) and the FEV1% was
91.6  24.4% (steroid dose 712  557 mcg/day). When the
FEV1 was <80% (n Z 12), FENO was similar as compared to
when it was >80% (17.2  11 vs. 18.9  16.2 ppb, respec-
tively, p Z 0.73).
A few moderate asthma exacerbations occurred during
the study period (8 out 120 study visits, mean steroid dose
316  493 mcg/day). At the time of these exacerbations the
ACT scores were significantly lower compared to the prior
visit (13.3  4.9 vs. 21.4  4, p < 0.02). FENO (34.5  29 vs.
24.8  14.7 ppb) and FEV1% (69  13% vs. 76.6  23.4%)
showed a trend for increase of FENO and decrease of the
FEV1%, but these did not reach statistical significance
(p > 0.19 for both).
Neither the baseline data, nor the results of the analysis
of associations were affected by limiting the statistical
analysis to the lifetime non smokers (data not shown).
Our results showing that FENO is not elevated in elderly
asthmatics are in agreement with a very recent study in
elderly asthmatics half of whom were on inhaled steroids
whose FENO was about 20 ppb.2 We did not find an asso-
ciation between FENO and subjects’ demographics
including age or with atopic disease as in a recent study
that found similar FENO levels in older and younger
Asthma in the elderly 787asthmatic adults.3 However, in another report FENO was
positively associated with the number of positive skin
tests.4
In adult asthmatics, FENO was found to be negatively but
weakly associated with the inhaled steroid dose.5 In
contrast, in elderly asthmatics we did not find an associa-
tion between FENO and steroid dose or other anti-
asthmatic drugs. However, we cannot rule out that in our
subjects inhaled steroids may inhibit FENO independent of
their dose.
In adult patients with asthma, FENO has been nega-
tively, but weakly associated with ACT scores6 and incon-
sistently with lung function. In our elderly subjects, FENO
was not associated with ACT scores or with spirometric
values except at visit 2. Our results are in agreement with a
very recent study in younger asthmatics on inhaled
steroids.7
Only a few moderate asthma exacerbations occurred
during the study period. While FENO increased and FEV1%
decreased, these values did not reach statistical signifi-
cance, possibly because of the small number of observa-
tions. However, a very recent study in adult subjects on
inhaled steroids similarly showed that FENO does not
consistently increase during severe asthma exacerbations.8
Limitations of our study include the relatively small
number of subjects, almost exclusively caucasians, and
that most subjects were well controlled on inhaled ste-
roids. However, our results are in agreement with several
recent studies and our study schedule reproduces a rela-
tively typical “real life” clinical scenario.
In conclusion, our study shows that in stable elderly
asthmatics on inhaled steroids FENO is not elevated and
routine measurements of FENO may not be clinically valu-
able. Our results need confirmation in larger cohorts of
elderly asthmatics including subjects untreated with
inhaled steroids and those experiencing severe
exacerbations.
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